For Lilly, cash-pay is key in the US and, increasingly, abroad
Endpoints NewsTopic alignment 85
Eli Lilly already knows Americans are willing to shell out hundreds of dollars a month for obesity drugs. Its bet on selling directly to patients helped it build a substantial
Filed under
- GLP-1 cost managementmatch 85
How to measure the long-term value of GLP-1s within employer healthcare costs
HFMATopic alignment 92
Medicare Plans Rarely Cover Anti-Obesity Drugs for Other FDA-Approved Purposes
USC SchaefferTopic alignment 95
Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”
MedCity NewsTopic alignment 86
#AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
Endpoints NewsTopic alignment 86